Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

MGD007

Bispecific antibody · Immune activation, directed at glycoprotein A33 (gpA33) and CD3 complex · developed by MacroGenics

Phase 1/2 Most advanced trial (none active)
MGNX Developer
2 Registered trials

What is MGD007?

MGD007 is a humanized bispecific antibody that binds glycoprotein A33 (gpA33) on tumor cells and the CD3 complex on T cells. By crosslinking cytotoxic T lymphocytes to gpA33-expressing cells, it is intended to trigger T-cell-mediated lysis of those cells. It is studied in metastatic colorectal cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Bispecific antibody
Targets
glycoprotein A33 (gpA33), CD3 complex
Mechanism
Immune activation, directed at glycoprotein A33 (gpA33) and CD3 complex
Pathways
T-cell mediated cytotoxicity
Therapy area
Oncology
Developer
MacroGenics (MGNX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
OZ8N9U6CEH

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03531632 Phase 1/2 Colorectal Cancer Metastatic Completed MGNX
NCT02248805 Phase 1 Colorectal Carcinoma Completed MGNX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Colorectal Cancer MetastaticColorectal Carcinoma

More from MacroGenics

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the MGNX page.

Follow MGNX, the company behind MGD007

See MGNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MGNX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.